Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 355-364

  Merrill, Debra P ^b   Moonis, Mona ^b   Chou, Ting Chao ^b   Hirsch, Martin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NEVIRAPINE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0030042695     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.355     Document Type: Article

References (13)

1. Larder BA. Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance. In: Skalka AM, Goff SP, eds. Reverse transcriptases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1993:205-22.
2. McLeod GX, McGrath JM, Ladd EA, Hammer SM. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type-1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother 1992;36:920-5.
3. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
4. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
5. Reichman RC, Tejani N, Lambert JL, et al. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. Antiviral Res 1993;20:267-77.
6. Fitzgibbon JE, Howell RM, Haberzettl CA, et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992;36:153-7.
7. Zhang D, Caliendo AM, Eron JJ, et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994;38:282-7.
8. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-92.
9. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
10. Condra JH, Schleif AWA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
11. Caliendo AM, Hirsch MS. Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994;18:516-24.
12. Wilson CC, Hirsch MS. Combination antiretroviral therapy for the treatment of human immunodeficiency virus type-1 infection. Proc Assoc Am Phys 1995;107:19-27.
13. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33.